MedPath

DSJ-2016-07 ATTUNE® Cementless CR RP Japan

Not Applicable
Completed
Conditions
Osteoarthritis
Interventions
Device: Cementless Total Knee Arthroplasty
Registration Number
NCT03193034
Lead Sponsor
DePuy Orthopaedics
Brief Summary

The primary objective is to investigate the change from pre-operative baseline to two year postoperative functional performance improvement for the ATTUNE® primary, cementless TKA RP system as measured with the KOOS questionnaire (KOOS-ADL sub-score) in the Japanese patient population.

Detailed Description

* Evaluate change from preoperative baseline in post-operative outcomes using additional patient reported measures at 2 years: PKIP (overall and sub-scores), KOOS (overall and sub-scores), AKS and EQ-5D-3L.

* Evaluate change from preoperative baseline in pain and satisfaction over time as measured using a modified VAS Pain Score (discrete numbers rather than a continual scale) at 2yr.

* Evaluate type and frequency of Adverse Events

* Evaluate survivorship of the ATTUNE® Primary Cementless TKA system for the CR RP configurations using Kaplan-Meier survival analysis at 1 and 2yrs.

* Evaluate primary, cementless ATTUNE® TKA fixation through zonal radiographic analysis of the bone-implant interface at 6wk, 1yr, and 2yrs after surgery.

* Evaluate any changes in anatomic tibiofemoral, femoral component and tibial component alignment at 2 years compared to the first postoperative radiographs.

* Radiographically characterize the postoperative ATTUNE patellar component alignment and positioning in Japanese population.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
81
Inclusion Criteria
  • Subject is male or female and between the ages of 22 and 80 years at the time of surgery, inclusive.
  • Subject was diagnosed with NIDJD.
  • Subject, in the opinion of the Investigator, is a suitable candidate for cementless primary TKA using the devices described in this CIP with either resurfaced or non-resurfaced patellae.

Subject that is willing to give voluntary, written informed consent to participate in this clinical investigation and authorize the transfer of his/her information to the Sponsor .

  • Subject is currently not bedridden
  • Subject, in the opinion of the Investigator, is able to understand this clinical investigation and is willing and able to perform all study procedures and follow-up visits and co-operate with investigational procedures.
  • Subject is able to read, and comprehend the Informed Consent Document as well as complete the required PROs in Japanese.
Exclusion Criteria
  • The Subject is a woman who is pregnant or lactating. -Contralateral knee has already been enrolled in this study
  • Subject had a contralateral amputation.
  • Previous partial knee replacement (unicompartmental, bicompartmental or patellofemoral joint replacement), patellectomy, high tibial osteotomy or primary TKA in affected knee.
  • Subject is currently diagnosed with radicular pain from the spine that radiates into the limb to receive TKA.
  • Subject has participated in a clinical investig ation with an investigational product (drug or device) in the last three (3) months.
  • Subject is currently involved in any personal injury litigation, medical-legal or Worker's Acc ident Insurance claims (similar to Workers Compensation in USA).
  • Subject, in the opinion of the Investigator, is a drug or alcohol abuser (in the last 5 years) or has a psychological disorder that could affect their ability to complete patient reported question naires or be compliant with follow-up requirements.
  • Subject was diagnosed and is taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia.
  • Subject has a significant neurological or musculoskeletal disorder(s) or disease that may adversely affect gait or weight bearing (e.g., muscular dystrophy, multiple sclerosis, Charcot disease).
  • Subject is suffering from inflammatory arthritis (e.g., rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc.).
  • Subject has a medical condition with less than two (2) years life expectancy.
  • Uncontrolled gout

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
ATTUNE Cementless RP TKACementless Total Knee ArthroplastySubjects will receive a cementless, rotating platform total knee arthroplasty.
Primary Outcome Measures
NameTimeMethod
Patient-reported Outcome:Knee Injury and Osteoarthritis Outcome Score Activities of Daily Living (KOOS ADL)Minimum 2 years (670-912 days after surgery)

The Knee injury and Osteoarthritis Outcome Score (KOOS) is a patient self-administered questionnaire that consists of 42 questions and include the WOMAC Osteoarthritis index. The KOOS consists of 5 subscales: pain, other symptoms, activities of daily living (ADL), sport and recreational function and knee related quality of life. Each question has 5 Likert-like response options. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.

Secondary Outcome Measures
NameTimeMethod
Modified VAS Pain Score: Pain and SatisfactionMinimum 2 years (670-912 days after surgery)

VAS Pain Score is a standardized instrument for use as a measure of pain and satisfaction that is designed for completion by the subject. This modified version has scores that are discrete numbers rather than a continual scale

Implant fixation: Radiographic assessment of bone-implant interface performance6 weeks (1-303 days after surgery), minimum 1 year (304-669 days after surgery), minimum 2 years (670-912 days after surgery)

Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change \>3degrees in any plane.

Patient-reported Outcome: Knee Injury and Osteoarthritis Outcome Score (KOOS)Minimum 2 years (670-912 days after surgery)

The Knee injury and Osteoarthritis Outcome Score (KOOS) is a patient self-administered questionnaire that consists of 42 questions and include the WOMAC Osteoarthritis index. The KOOS consists of 5 subscales: pain, other symptoms, activities of daily living (ADL), sport and recreational function and knee related quality of life. Each question has 5 Likert-like response options. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.

SurvivorshipMinimum 1 year (304-669 days after surgery), minimum 2 years (670-912 days after surgery)

Kaplan-Meier survival analysis will be used to calculate the survivorship of configuration (CR RP)

Patient-reported Outcome: Pre-surgical/Post-surgical Patient's Knee Implant Performance (PKIP)Minimum 2 years (670-912 days after surgery)

The Pre Surgical and/or Post-surgical Patient's Knee Implant Performance (PKIP) questionnaire is a patient self-administered questionnaire that consists of 25 questions relating to the patient's awareness of their knee. Questions include the patient's self-confidence about the current status of their knee performance, stability, and overall satisfaction. Each question has a 5, 6 or 10 Likert- like response option.

Combination of Patient-reported and Clinical-reported Outcome: Knee Society 2011Minimum 2 years (670-912 days after surgery)

The Knee Society Score is a self-administered questionnaire. The subject completes questions regarding: Symptoms (3 questions), Patient Satisfaction (5 questions), Patient Expectations (3 questions), Functional Activities (5 questions), Standard Activities (6 questions), Advanced Activities (5 questions), and Discretionary Knee Activities ( 4 questions). The surgeon completes questions regarding objective knee indicators. Likert responses are used, typically with five response options.

Patient Reported Outcome: EuroQol 5D 3L questionnaire (EQ-5D-3L)Minimum 2 years (670-912 days after surgery)

EuroQol 5D 3L questionnaire is a standardized instrument for use as a measure of health outcome that is designed for completion by the subject.

Type and Frequency of Adverse Events (AEs) for all enrolled subjectsPre-op (-180 to -1 days before surgery), 6 weeks (1-303 days after surgery), minimum 1 year (304-669 days after surgery), minimum 2 years (670-912 days after surgery)

All Serious AEs must be reported to Sponsor. All device-related or procedure-related adverse events must be reported to Sponsor.

Evaluate changes in femoral component and tibial component alignmentMinimum 2 years (670-912 days after surgery)

Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change \>3degrees in any plane.

Radiographically characterize the postoperative ATTUNE patellar component alignment and positioning in Japanese population.Minimum 1 year (304-669 days after surgery)

Evaluate the tilt angle and translational position of the patellar component relative to the trochlear groove.

Trial Locations

Locations (4)

Kobe University Graduate School of Medicine

🇯🇵

Kobe, Hyogo, Japan

Nagoya City University Hospital

🇯🇵

Nagoya, Aichi, Japan

Nagoya orthopedic Clinic

🇯🇵

Kitanagoya, Aichi, Japan

Osaka Rosai Hospital

🇯🇵

Sakai, Osaka, Japan

© Copyright 2025. All Rights Reserved by MedPath